^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CDR404

    i
    Other names: CDR404, CDR 404, CDR-404
    Associations

    News

    Trials
    Company:
    CDR-Life
    Drug class:
    MAGE-A4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors (clinicaltrials.gov)
    P1, N=42, Recruiting, CDR-Life AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CDR404
    6ms
    First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, CDR-Life AG
    New P1 trial
    |
    CDR404
    7ms
    In silico tumor immune microenvironment (TiME) analysis of non-small cell lung cancer (NSCLC) to inform clinical development of CDR404: A first-of-its-kind MAGE-A4 targeted T-cell engager. (ASCO 2024)
    LUSC MAGE-A4HIGH tumors had a differentiated TiME profile. Our findings are consistent with an INFLAMLOWVASCLOW phenotype possibly indicative of an "immune desert" [Desbois et al 2020]. In contrast, LUAD MAGE-A4HIGH tumors had an INFLAMHIGHVASCLOW phenotype indicating that MAGE-A4 associations with TiME may be histology dependent in NSCLC.
    Clinical
    |
    CD8 (cluster of differentiation 8) • MAGEA4 (Melanoma antigen family A, 4)
    |
    Tempus xR
    |
    CDR404
    1year
    CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC) (SITC 2023)
    Conclusions The high MAGE-A4 expression levels and the highly specific anti-cancer cell activity of CDR404 make it a highly attractive immunotherapy for development post-progression on ICI for patients with HLA-A*02:01+ SQ-NSCLC. A multi-tumor phase 1 trial of CDR404, including SQ-NSCLC, is expected to begin in 2024 with prospective patient selection for both HLA-A*02:01 and tumor MAGE-A4.
    IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    CDR404
    over1year
    Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager (ESMO 2023)
    Lack of response reported in another MAGE-A4 TCE trial (NCT03973333) where tumor screening in ovarian cancer was absent confirms that IHC selection will be essential for RNALOW tumors. In this regard, we have identified E7O1U as a highly specific MAGE-A4 antibody for precise IHC patient selection in the CDR404 trial.
    Clinical
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    CDR404